Etonogestrel

Etonogestrel
Systematic (IUPAC) name
(8S,9S,10R,13S,14S,17R)-13-Ethyl-17-ethynyl-17-hydroxy-11-methylidene-2,6,7,8,9,10,12,14,15,16-decahydro-1H-cyclopenta[a]phenanthren-3-one
Clinical data
AHFS/Drugs.com Multum Consumer Information
MedlinePlus a604032
Routes of
administration
Subdermal as slow-release implant
Legal status
Legal status
  • AU: S4 (Prescription only)
  • UK: POM (Prescription only)
  • US: -only
  • (Prescription only)
Pharmacokinetic data
Metabolism Hepatic (P450 3A4)
Biological half-life 25 hours
Excretion Urinary (majority) and fecal
Identifiers
CAS Number 54048-10-1 YesY
ATC code G03AC08 (WHO)
PubChem CID 21729469
IUPHAR/BPS 7590
DrugBank DB00294 YesY
ChemSpider 5292944 YesY
UNII 304GTH6RNH YesY
KEGG D04104 YesY
ChEBI CHEBI:50777 YesY
ChEMBL CHEMBL1531 YesY
Chemical data
Formula C22H28O2
Molar mass 324.457 g/mol
  (verify)

Etonogestrel is a steroidal progestin used in hormonal contraceptives, most notably the subdermal implant Nexplanon and the vaginal ring NuvaRing.

Etonogestrel is the active metabolite of the inactive prodrug desogestrel, one of two third-generation progestins found in some epidemiological studies of combined oral contraceptive pills to be associated with a higher risk of venous thrombosis than combined oral contraceptive pills containing certain second-generation progestins. Because hormones are released continuously from NuvaRing, peak and total estrogen and progestin doses are significantly lower than with combined oral contraceptives, although it is not known whether this lowers the risk of blood clots. It is effective within the first 24 hours.

References



    This article is issued from Wikipedia - version of the Saturday, April 02, 2016. The text is available under the Creative Commons Attribution/Share Alike but additional terms may apply for the media files.